SG11201502505UA - Modulation of androgen receptor expression - Google Patents

Modulation of androgen receptor expression

Info

Publication number
SG11201502505UA
SG11201502505UA SG11201502505UA SG11201502505UA SG11201502505UA SG 11201502505U A SG11201502505U A SG 11201502505UA SG 11201502505U A SG11201502505U A SG 11201502505UA SG 11201502505U A SG11201502505U A SG 11201502505UA SG 11201502505U A SG11201502505U A SG 11201502505UA
Authority
SG
Singapore
Prior art keywords
modulation
androgen receptor
receptor expression
expression
androgen
Prior art date
Application number
SG11201502505UA
Other languages
English (en)
Inventor
Robert A Macleod
Youngsoo Kim
Tianyuan Zhou
Susan M Freier
Punit P Seth
Eric Swayze
Brett P Monia
Original Assignee
Isis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50475891&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201502505U(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Isis Pharmaceuticals Inc filed Critical Isis Pharmaceuticals Inc
Publication of SG11201502505UA publication Critical patent/SG11201502505UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3525—MOE, methoxyethoxy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
SG11201502505UA 2012-10-11 2013-10-11 Modulation of androgen receptor expression SG11201502505UA (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261712780P 2012-10-11 2012-10-11
US201261712756P 2012-10-11 2012-10-11
US201261723701P 2012-11-07 2012-11-07
US201361777813P 2013-03-12 2013-03-12
US201361777895P 2013-03-12 2013-03-12
US201361777851P 2013-03-12 2013-03-12
PCT/US2013/064479 WO2014059238A2 (en) 2012-10-11 2013-10-11 Modulation of androgen receptor expression

Publications (1)

Publication Number Publication Date
SG11201502505UA true SG11201502505UA (en) 2015-04-29

Family

ID=50475891

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201502505UA SG11201502505UA (en) 2012-10-11 2013-10-11 Modulation of androgen receptor expression

Country Status (32)

Country Link
US (3) US9175291B2 (pt)
EP (1) EP2906226B1 (pt)
JP (2) JP6306598B2 (pt)
KR (1) KR102124228B1 (pt)
CN (2) CN104703610B (pt)
AP (1) AP2015008368A0 (pt)
AR (1) AR092982A1 (pt)
AU (2) AU2013329070A1 (pt)
BR (1) BR112015007878A2 (pt)
CA (1) CA2887867C (pt)
CL (1) CL2015000901A1 (pt)
CO (1) CO7400882A2 (pt)
DK (1) DK2906226T3 (pt)
DO (1) DOP2015000083A (pt)
EC (1) ECSP15012462A (pt)
ES (1) ES2706387T3 (pt)
HK (2) HK1213774A1 (pt)
IL (2) IL237855A0 (pt)
MX (1) MX369207B (pt)
NI (1) NI201500051A (pt)
NZ (1) NZ706151A (pt)
PE (1) PE20150722A1 (pt)
PH (1) PH12015500788A1 (pt)
PL (1) PL2906226T3 (pt)
PT (1) PT2906226T (pt)
RU (1) RU2670486C9 (pt)
SG (1) SG11201502505UA (pt)
TN (1) TN2015000140A1 (pt)
TW (1) TW201420594A (pt)
UY (1) UY35078A (pt)
WO (1) WO2014059238A2 (pt)
ZA (1) ZA201503203B (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3430907A1 (en) 2011-07-29 2019-01-23 Medivation Prostate Therapeutics LLC Treatment of breast cancer
US9175291B2 (en) * 2012-10-11 2015-11-03 Isis Pharmaceuticals Inc. Modulation of androgen receptor expression
US11761962B2 (en) 2014-03-28 2023-09-19 Opko Diagnostics, Llc Compositions and methods related to diagnosis of prostate cancer
EP3604556A1 (en) 2014-12-12 2020-02-05 Medivation Prostate Therapeutics LLC Method for predicting response to breast cancer therapeutic agents and method of treatment of breast cancer
ES2848377T3 (es) 2015-02-26 2021-08-09 Ionis Pharmaceuticals Inc Moduladores específicos de alelo de RODOPSINA P23H
MX2017012320A (es) 2015-03-27 2018-01-18 Opko Diagnostics Llc Estandares de antigeno prostatico y sus usos.
US10722527B2 (en) 2015-04-10 2020-07-28 Capsugel Belgium Nv Abiraterone acetate lipid formulations
WO2017000288A1 (zh) * 2015-07-01 2017-01-05 深圳市第二人民医院 一种检测与特发性无精子症相关的遗传标记的引物对
EP3353306A4 (en) * 2015-09-25 2019-06-05 Ionis Pharmaceuticals, Inc. ANTISENSE CONJUGATED COMPOUNDS AND THEIR USE
WO2017066697A1 (en) * 2015-10-14 2017-04-20 Dou Qingping Treatments and diagnostics for cancers
CN105541991B (zh) * 2015-12-16 2019-05-31 中国医科大学 Bap18在促进前列腺癌方面的应用
US10604759B2 (en) * 2016-01-15 2020-03-31 City Of Hope Targeting glioblastoma stem cells through the TLX-TET3 axis
WO2017143000A1 (en) * 2016-02-18 2017-08-24 Ionis Pharmaceuticals, Inc. Modulators of klk3 erna
WO2017207702A1 (en) * 2016-06-02 2017-12-07 Sint-Augustinus Androgen receptor splice variants and androgen deprivation therapy
JP2019535839A (ja) 2016-11-29 2019-12-12 ピュアテック ヘルス エルエルシー 治療剤の送達のためのエクソソーム
US10933134B2 (en) * 2017-03-16 2021-03-02 Memorial Sloan Kettering Cancer Center Combination therapies for treatment of cancer
AU2019218987A1 (en) 2018-02-12 2020-07-23 Ionis Pharmaceuticals, Inc. Modified compounds and uses thereof
WO2019190927A2 (en) * 2018-03-26 2019-10-03 Duke University Splice-switching oligonucleotides and methods of use
CN109321569B (zh) * 2018-10-29 2022-04-12 迈杰转化医学研究(苏州)有限公司 一种引物探针组合物及其应用
WO2020102560A1 (en) * 2018-11-14 2020-05-22 Board Of Regents, The University Of Texas System Methods for the treatment of small round cell tumors
TW202028222A (zh) * 2018-11-14 2020-08-01 美商Ionis製藥公司 Foxp3表現之調節劑
KR102473989B1 (ko) 2018-11-28 2022-12-07 (주)바이오니아 안드로젠 수용체 특이적 서열을 포함하는 이중나선 올리고뉴클레오티드 구조체, 및 이를 포함하는 탈모 예방 및 발모용 조성물
WO2020148400A1 (en) * 2019-01-16 2020-07-23 Stichting Katholieke Universiteit Antisense oligonucleotides for use in the treatment of crpc
CN109880931A (zh) * 2019-04-11 2019-06-14 江苏省农业科学院 一种丝瓜抗黄瓜花叶病毒cmv主效qtl的slaf-snp分子标记方法及应用
US20220323444A1 (en) * 2019-07-29 2022-10-13 The Medical College Of Wisconsin, Inc. Methods of Treating Advanced Prostate Cancer
EP4054655A4 (en) * 2019-11-08 2024-02-28 Ionis Pharmaceuticals, Inc. COMPOUNDS AND METHODS FOR REDUCING SPDEF EXPRESSION

Family Cites Families (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2699808A (en) 1944-10-06 1955-01-18 Mark W Lowe Apparatus for peeling tomatoes
US2699508A (en) 1951-12-21 1955-01-11 Selectronics Inc Method of mounting and construction of mounting for low frequency piezoelectric crystals
US5118800A (en) 1983-12-20 1992-06-02 California Institute Of Technology Oligonucleotides possessing a primary amino group in the terminal nucleotide
FR2567892B1 (fr) 1984-07-19 1989-02-17 Centre Nat Rech Scient Nouveaux oligonucleotides, leur procede de preparation et leurs applications comme mediateurs dans le developpement des effets des interferons
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5591722A (en) 1989-09-15 1997-01-07 Southern Research Institute 2'-deoxy-4'-thioribonucleosides and their antiviral activity
EP0942000B1 (en) 1989-10-24 2004-06-23 Isis Pharmaceuticals, Inc. 2'-Modified oligonucleotides
US5646265A (en) 1990-01-11 1997-07-08 Isis Pharmceuticals, Inc. Process for the preparation of 2'-O-alkyl purine phosphoramidites
US5670633A (en) 1990-01-11 1997-09-23 Isis Pharmaceuticals, Inc. Sugar modified oligonucleotides that detect and modulate gene expression
GB9009980D0 (en) 1990-05-03 1990-06-27 Amersham Int Plc Phosphoramidite derivatives,their preparation and the use thereof in the incorporation of reporter groups on synthetic oligonucleotides
ES2116977T3 (es) 1990-05-11 1998-08-01 Microprobe Corp Soportes solidos para ensayos de hibridacion de acidos nucleicos y metodos para inmovilizar oligonucleotidos de modo covalente.
US6582908B2 (en) 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
US5877160A (en) 1991-05-31 1999-03-02 Genta Incorporated Compositions and methods of treatment of androgen-associated baldness using antisense oligomers
US7517644B1 (en) 1991-08-23 2009-04-14 Larry J. Smith Method and compositions for cellular reprogramming
ES2103918T3 (es) 1991-10-17 1997-10-01 Ciba Geigy Ag Nucleosidos biciclicos, oligonucleotidos, procedimiento para su obtencion y productos intermedios.
US5359044A (en) 1991-12-13 1994-10-25 Isis Pharmaceuticals Cyclobutyl oligonucleotide surrogates
FR2687679B1 (fr) 1992-02-05 1994-10-28 Centre Nat Rech Scient Oligothionucleotides.
EP0577558A2 (de) 1992-07-01 1994-01-05 Ciba-Geigy Ag Carbocyclische Nukleoside mit bicyclischen Ringen, Oligonukleotide daraus, Verfahren zu deren Herstellung, deren Verwendung und Zwischenproduckte
JPH08504559A (ja) 1992-12-14 1996-05-14 ハネウエル・インコーポレーテッド 個別に制御される冗長巻線を有するモータシステム
WO1994018835A1 (en) 1993-02-19 1994-09-01 Genta Incorporated Treatment of androgen-associated baldness using antisense oligomers
DK0691968T3 (da) 1993-03-30 1998-02-23 Sanofi Sa Acykliske nukleosid-analoge og oligonukleotidsekvenser indeholdende disse
US5801154A (en) 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US5556956A (en) 1993-11-04 1996-09-17 Board Of Regents, The University Of Texas System Methods and compositions relating to the androgen receptor gene and uses thereof
US5446137B1 (en) 1993-12-09 1998-10-06 Behringwerke Ag Oligonucleotides containing 4'-substituted nucleotides
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5627053A (en) 1994-03-29 1997-05-06 Ribozyme Pharmaceuticals, Inc. 2'deoxy-2'-alkylnucleotide containing nucleic acid
US5597909A (en) 1994-08-25 1997-01-28 Chiron Corporation Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use
AU7366296A (en) 1995-09-20 1997-04-09 Worcester Foundation For Biomedical Research, Inc. Antisense oligonucleotide chemotherapy for benign hyperplasia or cancer of the prostate
US6300060B1 (en) 1995-11-09 2001-10-09 Dana-Farber Cancer Institute, Inc. Method for predicting the risk of prostate cancer morbidity and mortality
US5656408A (en) 1996-04-29 1997-08-12 Xerox Corporation Coated carrier particles
US6489163B1 (en) 1996-05-08 2002-12-03 Board Of Regents, The University Of Texas System Ribozyme mediated inactivation of the androgen receptor
WO2005121370A2 (en) 2004-06-03 2005-12-22 Isis Pharmaceuticals, Inc. Oligomeric compounds that facilitate risc loading
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
US6770748B2 (en) 1997-03-07 2004-08-03 Takeshi Imanishi Bicyclonucleoside and oligonucleotide analogue
US5994076A (en) 1997-05-21 1999-11-30 Clontech Laboratories, Inc. Methods of assaying differential expression
EP1557424A1 (en) 1997-09-12 2005-07-27 Exiqon A/S Bi-cyclic nucleoside, nucleotide and oligonucleoide analogues
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US20030228597A1 (en) 1998-04-13 2003-12-11 Cowsert Lex M. Identification of genetic targets for modulation by oligonucleotides and generation of oligonucleotides for gene modulation
US6043352A (en) 1998-08-07 2000-03-28 Isis Pharmaceuticals, Inc. 2'-O-Dimethylaminoethyloxyethyl-modified oligonucleotides
CA2343835A1 (en) 1998-09-15 2000-03-23 Signalgene Inc. Marker at the androgen receptor gene for determining breast cancer susceptibility
WO2000063364A2 (en) 1999-04-21 2000-10-26 American Home Products Corporation Methods and compositions for inhibiting the function of polynucleotide sequences
ES2283298T3 (es) 1999-05-04 2007-11-01 Santaris Pharma A/S Analogos de l-ribo-lna.
US6525191B1 (en) 1999-05-11 2003-02-25 Kanda S. Ramasamy Conformationally constrained L-nucleosides
AU2698301A (en) 1999-12-30 2001-07-16 K.U. Leuven Research And Development Cyclohexene nucleic acids
US6255110B1 (en) 2000-01-21 2001-07-03 Isis Pharmaceuticals, Inc. Antisense modulation of ARA70 expression
AU2001244004A1 (en) 2000-03-28 2001-10-08 Signalgene Inc. Method for determining osteoporosis susceptibility and/or low bone density and reagents therefor
US20040241651A1 (en) 2000-04-07 2004-12-02 Alexander Olek Detection of single nucleotide polymorphisms (snp's) and cytosine-methylations
US6784291B2 (en) 2000-05-04 2004-08-31 Avi Biopharma, Inc. Splice-region antisense composition and method
WO2002000716A2 (en) 2000-06-28 2002-01-03 Bristol-Myers Squibb Company Cell lines and cell-based assays for identification of androgen receptor modulators
US6960474B2 (en) 2000-06-28 2005-11-01 Bristol-Myers Squibb Company Method for the treatment of a condition remediable by administration of a selective androgen receptor modulator
RU2003102390A (ru) * 2000-06-28 2004-05-27 Бристол-Маерс Сквибб Компани (Us) Селективные модуляторы рецептора андрогена и способы их идентификации, изготовления и применения
AU2001278068A1 (en) 2000-07-27 2002-02-13 University Of Rochester Methods and compositions for predicting prostate cancer
US20020165381A1 (en) 2000-11-30 2002-11-07 Isabelle Ahrens-Fath Human androgen receptor variants
JP2002247986A (ja) 2001-02-23 2002-09-03 Mitsui Chemicals Inc 性ホルモン受容体作用評価に有用な細胞
US20070021360A1 (en) 2001-04-24 2007-01-25 Nyce Jonathan W Compositions, formulations and kit with anti-sense oligonucleotide and anti-inflammatory steroid and/or obiquinone for treatment of respiratory and lung disesase
US20050159376A1 (en) 2002-02-20 2005-07-21 Slrna Therapeutics, Inc. RNA interference mediated inhibition 5-alpha reductase and androgen receptor gene expression using short interfering nucleic acid (siNA)
JP2005504020A (ja) 2001-07-03 2005-02-10 アイシス・ファーマシューティカルス・インコーポレーテッド ヌクレアーゼ耐性キメラオリゴヌクレオチド
US6680342B2 (en) 2001-09-20 2004-01-20 Mayo Foundation For Medical Education And Research Methods and compositions for inhibiting the proliferation of prostate cancer cells
FR2832154B1 (fr) 2001-11-09 2007-03-16 Centre Nat Rech Scient Oligonucleotides inhibiteurs et leur utilisation pour reprimer specifiquement un gene
US6861432B2 (en) 2001-11-23 2005-03-01 Schering Aktiengesellschaft Piperazine derivatives that destabilize androgen receptors
JP2004008140A (ja) 2002-06-10 2004-01-15 Sumitomo Chem Co Ltd 変異型アンドロゲンレセプターおよびその活性評価用細胞
EP1540004A4 (en) 2002-07-31 2007-10-03 Nucleonics Inc DOUBLE-STRING RNA STRUCTURES AND CONSTRUCTS AND METHOD FOR THE PRODUCTION AND USE THEREOF
AU2003284323A1 (en) 2002-10-18 2004-05-04 Alnylam Pharmaceuticals Inc Double-stranded rna structures and constructs, and methods for generating and using the same
CA2504044A1 (en) 2002-11-01 2004-05-21 Merck & Co., Inc. Carbonylamino-benzimidazole derivatives as androgen receptor modulators
AU2003291753B2 (en) 2002-11-05 2010-07-08 Isis Pharmaceuticals, Inc. Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
AU2003287502B2 (en) 2002-11-05 2010-12-09 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
DK2284266T3 (da) 2002-11-14 2014-01-13 Thermo Fisher Scient Biosciences Inc sIRNA-MOLEKYLE MOD TP53
US6673661B1 (en) 2002-12-20 2004-01-06 Taiwan Semiconductor Manufacturing Co., Ltd. Self-aligned method for forming dual gate thin film transistor (TFT) device
CA2512337A1 (en) 2003-01-03 2004-07-29 Gencia Corporation Sirna mediated post-transcriptional gene silencing of genes involved in alopecia
WO2004065379A1 (en) 2003-01-17 2004-08-05 Warner-Lambert Company Llc Androgen receptor antagonists
JP2004254600A (ja) 2003-02-26 2004-09-16 Sumitomo Chem Co Ltd 変異型アンドロゲンレセプターおよびその活性評価用細胞
JP2004254601A (ja) 2003-02-26 2004-09-16 Sumitomo Chem Co Ltd 変異型アンドロゲンレセプターおよびその活性評価用細胞
DE10322108B4 (de) 2003-05-09 2008-12-11 Bayer Schering Pharma Aktiengesellschaft Antiandrogene Pyrrolidine mit tumorhemmender Wirksamkeit
WO2004106356A1 (en) 2003-05-27 2004-12-09 Syddansk Universitet Functionalized nucleotide derivatives
ATE555118T1 (de) 2003-08-28 2012-05-15 Takeshi Imanishi Neue synthetische nukleidsäuren vom typ mit quervernetzter n-o-bindung
JP5379347B2 (ja) 2003-09-18 2013-12-25 アイシス ファーマシューティカルズ， インコーポレーテッド ４’−チオヌクレオシドおよびオリゴマー化合物
US20050164970A1 (en) 2003-12-22 2005-07-28 University Of Kansas Medical Center Method for treating prostate cancer using siRNA duplex for androgen receptor
US20050244851A1 (en) 2004-01-13 2005-11-03 Affymetrix, Inc. Methods of analysis of alternative splicing in human
CA2558682A1 (en) 2004-02-20 2005-09-01 Genesis Research And Development Corporation Limited Targeted delivery of rna interference molecules for the treatment of ige-mediated disorders
US7696241B2 (en) 2004-03-04 2010-04-13 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
JPWO2005116204A1 (ja) 2004-05-11 2008-06-19 株式会社アルファジェン Ｒｎａ干渉を生じさせるポリヌクレオチド、および、これを用いた遺伝子発現抑制方法
US7268232B2 (en) 2004-05-17 2007-09-11 Acadia Pharmaceuticals Inc. Androgen receptor modulators and method of treating disease using the same
DE102004025881A1 (de) 2004-05-19 2006-01-05 Beiersdorf Ag Oligoribonukleotide zur Beeinflussung des Haarwachstums
JP5192234B2 (ja) 2004-08-10 2013-05-08 アルナイラム ファーマシューティカルズ， インコーポレイテッド 化学修飾オリゴヌクレオチド
EP1812569A2 (en) 2004-11-08 2007-08-01 K.U. Leuven Research and Development Modified nucleosides for rna interference
EP1864134A4 (en) 2005-02-07 2010-10-20 Univ Columbia METHODS OF TREATING OR PREVENTING HORMONE-RESISTANT PROSTATE CANCER USING SMALL INTERFERING RNA SPECIFIC TO PROTOCADHERINE-PC, OR OTHER INHIBITORS OF PROTOCADHERINE-PC EXPRESSION OR ACTIVITY
US8795987B2 (en) 2005-02-11 2014-08-05 International Business Machines Corporation Ribonucleic acid interference molecules of Oryza sativa
US8912317B2 (en) 2005-02-11 2014-12-16 International Business Machines Corporation Ribonucleic acid interference molecules of Arabidopsis thaliana
US20070154896A1 (en) 2005-02-11 2007-07-05 International Business Machines Corporation System and method for identification of MicroRNA target sites and corresponding targeting MicroRNA sequences
US20070213293A1 (en) 2005-04-08 2007-09-13 Nastech Pharmaceutical Company Inc. Rnai therapeutic for respiratory virus infection
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
US20070111227A1 (en) 2005-07-28 2007-05-17 Green Pamela J Small regulatory RNAs and methods of use
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
AU2007211080B9 (en) 2006-01-27 2012-05-03 Isis Pharmaceuticals, Inc. 6-modified bicyclic nucleic acid analogs
JP4961549B2 (ja) 2006-02-16 2012-06-27 国立大学法人愛媛大学 アンドロゲン受容体遺伝子に特異的なｓｉＲＮＡ
US8178503B2 (en) 2006-03-03 2012-05-15 International Business Machines Corporation Ribonucleic acid interference molecules and binding sites derived by analyzing intergenic and intronic regions of genomes
PL2656841T3 (pl) 2006-03-27 2017-01-31 The Regents Of The University Of California Modulator receptora androgenowego do leczenia raka gruczołu krokowego i chorób związanych z receptorem androgenowym
JP2007282598A (ja) 2006-04-19 2007-11-01 Japan Health Science Foundation 性分化異常症診断マーカー
US7547684B2 (en) 2006-05-11 2009-06-16 Isis Pharmaceuticals, Inc. 5′-modified bicyclic nucleic acid analogs
JP4798093B2 (ja) 2006-08-04 2011-10-19 日産自動車株式会社 流体改質装置及びこれを用いた流体改質方法
AR055648A1 (es) 2006-09-21 2007-08-29 Gen Med Sa Un oligonucleotido de rna de doble cadena una composicion farmaceutica o cosmetica que lo comprende y uso del mismo enla preparacion de un medicamento para el tratamiento de enfermedades relacionadas con el metabolismo de androgenos
EP2140027B1 (en) 2006-12-07 2012-07-18 Novartis AG Non-invasive prenatal genetic screen
US7960435B2 (en) 2006-12-15 2011-06-14 University Of Maryland, Baltimore Anti-cancer agents and androgen inhibition activity compound
US20100190837A1 (en) 2007-02-15 2010-07-29 Isis Pharmaceuticals, Inc. 5'-Substituted-2-F' Modified Nucleosides and Oligomeric Compounds Prepared Therefrom
WO2008119015A2 (en) 2007-03-27 2008-10-02 Sloan-Kettering Institute For Cancer Research Synthesis of thiohydantoins
CA2688321A1 (en) 2007-05-30 2008-12-11 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
DK2173760T4 (en) 2007-06-08 2016-02-08 Isis Pharmaceuticals Inc Carbocyclic bicyclic nukleinsyreanaloge
ES2376507T5 (es) 2007-07-05 2015-08-31 Isis Pharmaceuticals, Inc. Análogos de ácidos nucleicos bicíclicos 6-disustituidos
NZ584827A (en) * 2007-10-01 2012-10-26 Isis Pharmaceuticals Inc Antisense modulation of fibroblast growth factor receptor 4 expression
US8546556B2 (en) 2007-11-21 2013-10-01 Isis Pharmaceuticals, Inc Carbocyclic alpha-L-bicyclic nucleic acid analogs
US8450290B2 (en) 2007-11-26 2013-05-28 Enzon Pharmaceuticals, Inc. Methods for treating androgen receptor dependent disorders including cancers
MX2010005703A (es) 2007-11-26 2010-06-11 Enzon Pharmaceuticals Inc Antagonistas de acido nucleico entrelazado que eligen como objetivo al receptor de androgeno.
PE20091157A1 (es) 2007-12-21 2009-09-03 Astrazeneca Ab Derivados biciclicos para usar en el tratamiento de afecciones asociadas con el receptor de androgeno - 155
WO2009100320A2 (en) 2008-02-07 2009-08-13 Isis Pharmaceuticals, Inc. Bicyclic cyclohexitol nucleic acid analogs
AU2009215168A1 (en) 2008-02-12 2009-08-20 Dana-Farber Cancer Institute Fish assay for EML4 and ALK fusion in lung cancer
FR2929292A1 (fr) 2008-03-28 2009-10-02 Exonhit Therapeutics S A Sa Procede et methodes de diagnostic de la maladie d'alzheimer
US20090282496A1 (en) 2008-04-04 2009-11-12 University Of Rochester Medical Center Androgen Receptor Related Methods for Treating Bladder Cancer
CA2721506C (en) 2008-04-16 2019-09-17 Jun Luo Compositions and methods for treating or preventing prostate cancer and for detecting androgen receptor variants
EP2331141B1 (en) 2008-08-25 2016-01-06 Excaliard Pharmaceuticals, Inc. Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
US8133724B2 (en) 2008-09-17 2012-03-13 University Of Maryland, Baltimore Human androgen receptor alternative splice variants as biomarkers and therapeutic targets
DK2361256T3 (da) 2008-09-24 2013-07-01 Isis Pharmaceuticals Inc Cyclohexenyl-nukleinsyreanaloger
EP2356129B1 (en) 2008-09-24 2013-04-03 Isis Pharmaceuticals, Inc. Substituted alpha-l-bicyclic nucleosides
WO2010062914A1 (en) 2008-11-26 2010-06-03 The Johns Hopkins University Methods for identifying cancer risk
US8202690B2 (en) 2008-11-28 2012-06-19 Hisamitsu Pharmaceutical Co., Inc. Cancer marker and therapeutic agent for cancer
EP2451476A4 (en) 2009-07-06 2013-07-03 Alnylam Pharmaceuticals Inc BIOTRAITEMENT BASED ON CELLS
US20140154783A1 (en) 2009-07-06 2014-06-05 Alnylam Pharmaceuticals, Inc. Bioprocessing
SG10201907588XA (en) 2010-02-16 2019-09-27 Aragon Pharmaceuticals Inc Androgen Receptor Modulators And Uses Thereof
WO2011112581A1 (en) 2010-03-08 2011-09-15 Regents Of The University Of Minnesota Androgen receptor isoforms and methods
US9068185B2 (en) 2010-03-12 2015-06-30 Sarepta Therapeutics, Inc. Antisense modulation of nuclear hormone receptors
US8993738B2 (en) 2010-04-28 2015-03-31 Isis Pharmaceuticals, Inc. Modified nucleosides, analogs thereof and oligomeric compounds prepared therefrom
KR101981705B1 (ko) 2010-05-28 2019-05-24 사렙타 쎄러퓨틱스, 인코퍼레이티드 변형된 서브유니트간 결합 및/또는 말단 그룹을 갖는 올리고뉴클레오타이드 유사체
WO2012005898A2 (en) 2010-06-15 2012-01-12 Alnylam Pharmaceuticals, Inc. Chinese hamster ovary (cho) cell transcriptome, corresponding sirnas and uses thereof
CA2804210A1 (en) * 2010-07-06 2012-01-12 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of androgen receptor by double-stranded rna
CN106434648A (zh) * 2010-07-19 2017-02-22 F·C·贝内特 肌强直性营养障碍蛋白激酶(dmpk)表达的调节
WO2012018881A2 (en) 2010-08-03 2012-02-09 Alnylam Pharmaceuticals, Inc. Methods and compositions for the regulation of rna
WO2012065051A1 (en) 2010-11-12 2012-05-18 Enzon Pharmaceuticals, Inc. Compositions and methods for treating androgen receptor dependent disorders including cancers
DK2655621T3 (en) 2010-12-20 2018-08-13 Massachusetts Gen Hospital Polycomb-associated non-coding RNAS
BR112013019803A2 (pt) 2011-02-02 2019-06-11 Excaliard Pharmaceuticals Inc método de tratar quelóides ou cicatrizes hipertróficas usando os compostos anti-sentido objetivando fator de desenvolvimento de tecido conjuntivo (ctgf)
EP3067421B1 (en) 2011-02-08 2018-10-10 Ionis Pharmaceuticals, Inc. Oligomeric compounds comprising bicyclic nucleotides and uses thereof
JP2014508528A (ja) * 2011-03-10 2014-04-10 オスロ ウニヴェルスィテーツスィーケフース ハーエフ 消化管癌の検出方法および検出マーカー
DK2751270T3 (en) 2011-08-29 2018-10-29 Ionis Pharmaceuticals Inc OLIGOMER-CONJUGATE COMPLEXES AND THEIR USE
WO2013120003A1 (en) 2012-02-08 2013-08-15 Isis Pharmaceuticals, Inc. Modulation of rna by repeat targeting
US9778706B2 (en) 2012-02-24 2017-10-03 Blackberry Limited Peekable user interface on a portable electronic device
US9984408B1 (en) 2012-05-30 2018-05-29 Amazon Technologies, Inc. Method, medium, and system for live video cooperative shopping
US9175291B2 (en) * 2012-10-11 2015-11-03 Isis Pharmaceuticals Inc. Modulation of androgen receptor expression

Also Published As

Publication number Publication date
DOP2015000083A (es) 2015-06-15
US9175291B2 (en) 2015-11-03
TN2015000140A1 (en) 2016-10-03
AU2017200759B2 (en) 2018-07-19
NZ706151A (en) 2018-11-30
WO2014059238A2 (en) 2014-04-17
TW201420594A (zh) 2014-06-01
HK1258404A1 (zh) 2019-11-08
AR092982A1 (es) 2015-05-13
US20160068846A1 (en) 2016-03-10
ECSP15012462A (es) 2015-12-31
AP2015008368A0 (en) 2015-04-30
EP2906226A2 (en) 2015-08-19
JP2018126141A (ja) 2018-08-16
DK2906226T3 (en) 2019-02-18
EP2906226A4 (en) 2016-06-08
IL237855A0 (en) 2015-05-31
HK1213774A1 (zh) 2016-07-15
US9567588B2 (en) 2017-02-14
WO2014059238A8 (en) 2015-04-16
USRE48461E1 (en) 2021-03-09
US20140107180A1 (en) 2014-04-17
JP6306598B2 (ja) 2018-04-04
PT2906226T (pt) 2019-02-25
CL2015000901A1 (es) 2016-02-26
CO7400882A2 (es) 2015-09-30
IL262218A (en) 2018-11-29
EP2906226B1 (en) 2018-11-21
PH12015500788A1 (en) 2015-06-15
MX369207B (es) 2019-10-31
CN108300718A (zh) 2018-07-20
MX2015004641A (es) 2015-07-14
NI201500051A (es) 2016-02-15
UY35078A (es) 2014-03-31
RU2670486C2 (ru) 2018-10-23
RU2015111672A (ru) 2016-12-10
WO2014059238A3 (en) 2014-06-19
AU2017200759A1 (en) 2017-03-02
CN108300718B (zh) 2022-02-22
KR102124228B1 (ko) 2020-06-17
ES2706387T3 (es) 2019-03-28
BR112015007878A2 (pt) 2017-11-28
AU2013329070A1 (en) 2015-04-16
JP2016501513A (ja) 2016-01-21
CA2887867C (en) 2019-09-24
CN104703610B (zh) 2018-03-23
PE20150722A1 (es) 2015-06-03
JP6599497B2 (ja) 2019-10-30
IL262218B (en) 2020-08-31
CN104703610A (zh) 2015-06-10
RU2670486C9 (ru) 2019-04-01
KR20150064210A (ko) 2015-06-10
ZA201503203B (en) 2016-09-28
PL2906226T3 (pl) 2019-04-30
CA2887867A1 (en) 2014-04-17

Similar Documents

Publication Publication Date Title
HK1258404A1 (zh) 雄激素受體表達的調節
HUS2100047I1 (hu) Egy androgén receptor modulátor kristályos formái
EP2864479A4 (en) MODULATION OF UBE3A-ATS EXPRESSION
EP2911666A4 (en) ANDROGENO-RESISTANT ANDROGEN RECEPTOR MODULATORS
IL266446A (en) Androgen synthesis modulators